Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 100.74M | 102.41M | 121.38M | 140.14M | 150.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.74M | 102.41M | 121.38M | 140.14M | 150.59M |
| Cost of Revenue | 13.92M | 16.74M | 20.40M | 21.40M | 23.72M |
| Gross Profit | 86.81M | 85.66M | 100.98M | 118.74M | 126.87M |
| SG&A Expenses | 142.11M | 150.50M | 159.43M | 163.54M | 169.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 343.23M | 382.85M | 402.60M | 428.71M | 463.25M |
| Operating Income | -242.50M | -280.45M | -281.22M | -288.57M | -312.66M |
| Income Before Tax | -255.98M | -288.08M | -284.36M | -291.45M | -317.91M |
| Income Tax Expenses | -866.00K | -594.00K | -1.01M | -837.00K | -519.00K |
| Earnings from Continuing Operations | -255.12 | -287.49 | -283.36 | -290.61 | -317.39 |
| Earnings from Discontinued Operations | 4.08M | -3.32M | -21.04M | -22.15M | -22.15M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -251.03M | -290.80M | -304.39M | -312.76M | -339.55M |
| EBIT | -242.50M | -280.45M | -281.22M | -288.57M | -312.66M |
| EBITDA | -208.88M | -245.15M | -243.08M | -248.41M | -270.51M |
| EPS Basic | -4.19 | -5.00 | -5.35 | -5.64 | -6.23 |
| Normalized Basic EPS | -2.38 | -2.84 | -2.86 | -2.97 | -3.29 |
| EPS Diluted | -4.20 | -5.01 | -5.36 | -5.65 | -6.23 |
| Normalized Diluted EPS | -2.38 | -2.84 | -2.86 | -2.97 | -3.29 |
| Average Basic Shares Outstanding | 242.71M | 234.37M | 227.14M | 221.82M | 218.55M |
| Average Diluted Shares Outstanding | 242.71M | 234.37M | 227.14M | 221.82M | 218.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |